Top-News
Biotechnologie USA

INHIBRX INC. News

Aktie
WKN:  A2PQMH ISIN:  US45720L1070
Keine aktuellen Kursdaten verfügbar
Handeln Depot/Watchlist
Aktienanzahl *
47,29 Mio.
Marktkapitalisierung *
708,94 Mio. €
Streubesitz
48,29%
Index-Zugehörigkeit
-
*Stand: 23.01.2024

INHIBRX INC. News

24.05.24 - PR Newswire
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi PR Newswire
10.05.24 - PR Newswire
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
Inhibrx, Inc. Announces Updated When-​Issued Trading Date for Anticipated Spin-Off PR Newswire
10.05.24 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWN, INBX, AVRO
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWN, INBX, AVRO PR Newswire
08.05.24 - PR Newswire
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger PR Newswire
28.03.24 - PR Newswire
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates WRK, TGAN, ANSS, INBX
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates WRK, TGAN, ANSS, INBX PR Newswire
26.03.24 - PR Newswire
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - HMST, FREE, EVBG, INBX
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - HMST, FREE, EVBG, INBX PR Newswire
19.03.24 - wallstreet:online Zentralredaktion
Neue Ära der Krebsbehandlung: Fusion Pharma von AstraZeneca für 2,4 Milliarden US-Dollar übernommen
Der britische Pharmakonzern Astra schnappt sich das kleine Biotech-​Unternehmen Fusion, um sich dessen Krebsbehandlung der nächsten Generation zu sichern. Was steckt ...
18.03.24 - PR Newswire
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates TAST, MDC, INBX
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates TAST, MDC, INBX PR Newswire
12.03.24 - PR Newswire
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates MDC, INBX, KAMN, HAYN
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates MDC, INBX, KAMN, HAYN PR Newswire
11.03.24 - PR Newswire
INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - INBX, KAMN, JNPR, HAYN
INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - INBX, KAMN, JNPR, HAYN PR Newswire
05.03.24 - PR Newswire
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates INBX, BATL, KAMN
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates INBX, BATL, KAMN PR Newswire
28.02.24 - PR Newswire
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results PR Newswire
12.02.24 - PR Newswire
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AMAM, JNPR, INBX, RYZB
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AMAM, JNPR, INBX, RYZB PR Newswire
29.01.24 - PR Newswire
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates INBX, KAMN, BATL
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates INBX, KAMN, BATL PR Newswire
26.01.24 - PR Newswire
Kuehn Law Encourages DOC, BATL, KAMN, and INBX Investors to Contact Law Firm
Kuehn Law Encourages DOC, BATL, KAMN, and INBX Investors to Contact Law Firm PR Newswire
23.01.24 - PR Newswire
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates INBX, SP, WAVD, CATC
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates INBX, SP, WAVD, CATC PR Newswire
23.01.24 - PR Newswire
Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi
Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi PR Newswire
23.01.24 - PR Newswire
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B PR Newswire
09.11.23 - PR Newswire
Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights PR Newswire
02.11.23 - PR Newswire
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma PR Newswire

Newssuche

Videos

newspaper
03.07.24
Technical Trading: Bund Future Long Chance
Bund Future Long Typ: Turbo Open End WKN: VM3CG4 Hebel: 7,32 Laufzeit: OpenEnd Einstieg: Market ... Mehr »